Xcout IntelSign inSubscribe

Blue Cell Therapeutics

BiotechnologyDenmark

Blue Cell Therapeutics is a biotechnology company founded in Copenhagen that focuses on revolutionizing the treatment of erectile dysfunction using specialized cell therapy.

Subscribe to see Blue Cell Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Blue Cell Therapeutics at a glance

Blue Cell Therapeutics is a biotechnology company headquartered in Denmark. Its most recent funding round, Angel, closed in October 2024. Xcout tracks 6 named people at Blue Cell Therapeutics, including Søren P. Sheikh (Chief Executive Officer).

Industry
Biotechnology
Headquarters
Denmark

Blue Cell Therapeutics leadership

  • Søren P. SheikhChief Executive Officer
  • Benjamin ClaassDirector of Development Operations
  • Olav HellebøChairman of the Board
  • Anella Stelsig RogaczewskiMember of the Board
  • Michael UlvemanMember of the Board
  • Ole VahlgrenMember of the Board

Blue Cell Therapeutics funding rounds

Every round on record:

DateRoundAmountInvestors
AngelUndisclosed1 named
GrantUndisclosed1 named

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Investors

Blue Cell Therapeutics competitors

A few of Blue Cell Therapeutics's closest competitors — see the full list of competitors and alternatives →

ADRバイオメディカルホールディングス3750 · BiotechnologyTokyo, Japan
67% matchPublic

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.

Market cap$44.8M
Employees13
ADRバイオメディカルホールディングス competitors & alternatives →

Get Blue Cell Therapeutics's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Blue Cell Therapeutics — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Blue Cell Therapeutics in Xcout Intel

  • 6 named people with titles, LinkedIn and board committees
  • 2 funding rounds with the investors in each, and who they co-invest with
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →